University of Pittsburgh studies broccoli-derived chemicals to prevent prostate cancer

December 22, 2003

PITTSBURGH, Dec. 22 - Fruits and vegetables are good for overall health, and a newly funded study at the University of Pittsburgh Cancer Institute (UPCI) may show that certain vegetables, such as broccoli, also offer protection against prostate cancer.

UPCI researcher Shivendra Singh, Ph.D., professor of pharmacology and urology at the University of Pittsburgh School of Medicine, has received a $1.7 million grant from the National Cancer Institute to study prostate cancer prevention by phytochemicals found in broccoli called isothiocyanates (ITCs).

"Clearly, what we eat has an effect on the development of diseases such as cancer," said Dr. Singh, also co-leader of UPCI's cancer biochemoprevention program. "However, we know little about the mechanisms by which certain edible plants like broccoli help our bodies fight prostate cancer and other diseases. Our goal with this study is to better understand the function and relationship of substances in broccoli that appear to be linked to inhibiting prostate cancer growth."

ITCs are substances in vegetables that are generated when vegetables are either cut or chewed. Previous research has demonstrated that ITCs are highly effective in affording protection against cancer in animal models induced by carcinogens including those in tobacco smoke. Epidemiological research also has shown that increased consumption of vegetables that contain ITCs significantly reduces the risk for prostate cancer.

Dr. Singh's laboratory has found that some naturally occurring ITCs are highly effective in suppressing the growth of human prostate cancer cells at concentrations that are achievable through dietary intake of cruciferous vegetables such as watercress and broccoli. In his current study, Dr. Singh seeks to further define the mechanisms by which ITCs induce apoptosis, or cancer cell death, to provide insights into the key structural relationships between ITCs and cell processes and to identify potential biomarkers that could be useful for future intervention trials involving ITCs.

"The knowledge we gain from this study will help guide us in formulating practical and effective nutritional strategies for the prevention and treatment of prostate cancer," said Dr. Singh. In addition to studies involving broccoli, Dr. Singh also is examining the effect of garlic on prostate cancer prevention.

In the United States, only 23 percent of adults eat five or more fruits and vegetables per day.
-end-
Clare Collins
Jocelyn Uhl
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL:
CollCX@upmc.edu
UhlJH@upmc.edu

University of Pittsburgh Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.